国产AV三级一区三区,亚洲人午夜射精精品日韩,国产精品香蕉一区二区三区

PC786

NMR下載 COA and HPLC MSDS下載
names：
PC786
CAS號：
1902114-15-1
MDL Number： NA
MF(分子式)： C41H38FN5O4S MW(分子量)： 715.83
EINECS:No data available Reaxys Number:No data available
Pubchem ID:121276461 Brand:BIOFOUNT

PC786(1902114-15-1)是一種吸入性呼吸道合胞病毒（RSV）L蛋白聚合酶抑制劑。 PC786對RSV-A和RSV-B表現出強大的抗病毒活性。PC786可能發揮作用的方式包括通過抑制病毒DNA聚合酶來防止病毒復制, 與特定的細胞表面受體結合并抑制病毒滲透或脫殼, 抑制病毒蛋白質合成, 或阻止病毒組裝的后期。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000876-250mg	250mg	>95%	￥ 0.00	￥ 0.00		Backorder	- +	￥ 0.00
YZM000876-100mg	100mg	>95%	￥ 0.00	￥ 0.00		Backorder	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	PC786(1902114-15-1);PC-786;PC 786
英文別名	PC786(1902114-15-1);PC-786;PC 786
CAS號	1902114-15-1
Inchi	InChI=1S/C41H38FN5O4S/c1-25-20-31(37(43-22-25)46-23-41(24-46)15-18-51-19-16-41)38(48)44-29-12-10-27(11-13-29)40(50)47-17-14-28-21-34(52-36(28)30-7-3-4-9-33(30)47)39(49)45-35-26(2)6-5-8-32(35)42/h3-13,20-22H,14-19,23-24H2,1-2H3,(H,44,48)(H,45,49)
InchiKey	VTCJNYICQADBJD-UHFFFAOYSA-N
分子式 Formula	C41H38FN5O4S
分子量 Molecular Weight	715.83
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions	請根據產品建議的存儲條件進行存儲,Please store the product under the recommended condition sin the description.

PC786(1902114-15-1)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染

PC786(1902114-15-1)Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:PC786(1902114-15-1),PC786試劑,PC786抑制劑,PC786的純度,PC786的作用,PC786的含量,PC786的外觀,PC786的溶解度,PC786的MSDS,PC786的合成,PC786的用途,PC786的生產,PC786的活性,PC786的圖譜

產品說明	PC786(1902114-15-1)是一種與酶結合的化合物或試劑，可防止正常的底物-酶結合和催化反應。
Introduction	PC786 (1902114-15-1) is a compound or reagent that binds to enzymes, which can prevent normal substrate-enzyme binding and catalyze reactions.
Application1
Application2
Application3

Structure-based drug designing and immunoinformatics approach for SARS-CoV-2
Abstract:The prevalence of respiratory illness caused by the novel SARS-CoV-2 virus associated with multiple organ failures is spreading rapidly because of its contagious human-to-human transmission and inadequate globalhealth care systems. Pharmaceutical repurposing, an effective drug development technique using existing drugs, could shorten development time and reduce costs compared to those of de novo drug discovery. We carried out virtual screening of antiviral compounds targeting the spike glycoprotein (S), main protease (Mpro), and the SARS-CoV-2 receptor binding domain (RBD)–angiotensin-converting enzyme 2 (ACE2) complex of SARS-CoV-2. PC786, an antiviral polymerase inhibitor, showed enhanced binding affinity to all the targets. Furthermore, the postfusion conformation of the trimeric S protein RBD with ACE2 revealed conformational changes associated with PC786 drug binding. Exploiting immunoinformatics to identify T cell and B cell epitopes could guide future experimental studies with a higher probability of discovering appropriate vaccine candidates with fewer experiments and higher reliability.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium

Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium PMID 29596680; The Journal of antimicrobial chemotherapy 2018 07; 73(7):1823-1829

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor PMID 28652242; Antimicrobial agents and chemotherapy 2017 09; 61(9):

Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium PMID 29596680; The Journal of antimicrobial chemotherapy 2018 07; 73(7):1823-1829

Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
PMID 29579332; British journal of pharmacology 2018 06; 175(12):2520-2534
Background and purpose: Effective anti-respiratory syncytial virus (RSV) agents are still not available for clinical use. Current major targets are virus surface proteins, such as a fusion protein involved in viral entry, but agents effective after RSV infection is established are required. Here we have investigated the effects of late therapeutic intervention with a novel inhaled RSV polymerase inhibitor, PC786, on RSV infection in human airway epithelium.
Experimental approach: Air liquid interface-cultured bronchial or small airway epithelium was infected with RSVA2. PC786 was applied apically or basolaterally once daily following peak virus load on Day 3 post inoculation. Apical wash was collected daily for determination of viral burden by PCR and plaque assay (primary endpoints) and biomarker analyses. The effects were compared with those of ALS-8112, an anti-RSV nucleoside analogue, and GS-5806, a fusion-protein inhibitor, which were treated basolaterally.
Key results: Late intervention with GS-5806 did not show significant anti-viral effects, but PC786 produced potent, concentration-dependent inhibition of viral replication with viral load falling below detectable limits 3 days after treatment commenced in airway epithelium. These effects were superior to those of ALS-8112. PC786 showed inhibitory activities against RSV-induced increases of CCL5, IL-6, double-strand DNA and mucin. The effects of PC786 were also confirmed in small airway epithelium.
Conclusion and implications: Late therapeutic intervention with the RSV polymerase inhibitor, PC786, reduced the viral burden quickly in human airway epithelium. Thus, PC786 demonstrates the potential to be an effective therapeutic agent to treat active RSV infection.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開